Search Results

You are looking at 141 - 150 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha

Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy

Full access

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

are now eligible for treatment with ICIs. 8 Due to the need for chronic immunosuppressive therapy, SOTRs with cancer have been consistently excluded from clinical trials with ICIs. 9 – 16 Thus, clinical outcomes for cancers arising in SOTRs treated

Full access

Puneeth Iyengar and Robert D. Timmerman

To understand why radiation oncologists moved toward the use of SABR in treating primary NSCLCs and metastatic disease to the lungs, the poor outcomes in controlling these disease states with fractionated radiation therapy (eg, 25–37 daily treatments

Full access

Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong

in survival over the past decade. 2 Advances in personalized therapies for advanced NSCLC (aNSCLC), which allow treatment based on the genetic makeup of a tumor, have significantly contributed to the improved outcomes of patients. 2 Despite the

Full access

Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas

chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration

Full access

Eric Chen, Todd Aquino-Michaels, Sadhvi Batra, Riley Lochner, Anthony Rizzo, Ravi Kyasaram, Eleanor Harris, Tiffany Hodges, Lindsay Ferguson, and Serah Choi

Background : Even among patients with stage IV gynecologic cancers, metastases to the brain are rare and prognosis remains poor. Given the paucity of data, this study aimed to describe the outcomes of this patient population who underwent

Full access

Krista Michelle Wong, Seshma Ramsawak, and Hasan Abuamsha

racial disparity in appendiceal cancer-specific survival exists among appendiceal cancer SEER patients. Further research is needed to address the underlying cause of these disparities in order to improve outcomes. Table: Bivariable and multivariable

Full access

Alejandro Garcia-Horton and Jeffrey H. Lipton

possible without widespread treatment and availability of TKIs, resulting in disease control and molecular response. Treatment-free remission (TFR) has emerged as a new goal for many patients with CML as a distinct outcome other than overall survival (OS

Full access

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

, 31% (n=68) of patients received no treatment ( Table 3 ). From 1995 to 1998, most patients did not receive any treatment. Liver-directed therapy became more prevalent from 2007 to 2010 ( Figure 2 ). Survival Outcomes No statistically

Full access

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

supporting evidence that it improves outcomes. 1 , 2 Yet imaging, either in response to patient symptoms or for surveillance, is common in the management of patients with ovarian cancer in first remission among providers at academic medical centers. 3 In a